Compare HY & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | SLDB |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 674.4M |
| IPO Year | 2012 | 2017 |
| Metric | HY | SLDB |
|---|---|---|
| Price | $35.33 | $6.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $16.36 |
| AVG Volume (30 Days) | 71.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | $8,094,000.00 |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.41 | $3.79 |
| 52 Week High | $44.55 | $8.87 |
| Indicator | HY | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 43.47 |
| Support Level | $35.16 | $6.20 |
| Resistance Level | $38.48 | $6.87 |
| Average True Range (ATR) | 1.62 | 0.42 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 74.33 | 34.00 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.